Patient-friendly, non-technical summary of research papers

January 2026 Research Update

This report covers research on Hurler syndrome published in PubMed in January 2026. For other months, see all research updates.

Last update: July 2, 2026

At a glance

IDUA variant range

Brazil data added more IDUA gene variants in MPS I.

Regional variant patterns

Common IDUA variants differed between Brazil and India.

Biobank-linked records

A national biobank linked samples and results for steadier diagnosis.

Genetic diagnosis focus

This month emphasized genetic testing and diagnosis, not new treatments. Studies mapped more IDUA variants and showed regional patterns, while some cases still needed enzyme testing when one genetic method did not find a cause.

Overview

This month focused on genetic testing and diagnosis in Hurler syndrome (MPS I), rather than on new treatments.

One clear update was how much genetic variety can sit under the same diagnosis. A study from Brazil found many different changes in the IDUA gene in people with MPS I. It also added newly described IDUA variants to the overall list.

At the same time, the research highlighted that some gene changes show up more often in specific places. In the Brazil dataset, two IDUA variants were especially common. In an Indian national biobank, a different IDUA variant appeared repeatedly in their Hurler syndrome data. This helps explain why genetic confirmation may be more straightforward for some families in some regions than others.

The Indian biobank report also showed what shared samples and linked clinical and lab information can do over time. It supported more consistent diagnosis across centers. It also noted that enzyme testing can support a diagnosis even when one genetic method does not find a causative change.

Get the monthly update by email

Subscribe here to receive an email when a new monthly Hurler syndrome update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).

Research topics this month

This month added clearer detail to the genetic side of Hurler syndrome (MPS I): many different IDUA gene changes can cause the condition, but some repeats are common in specific countries. These studies also showed that building shared sample and data resources can make it easier for centers to confirm diagnoses and compare findings over time. Together, they strengthen the picture that both genetic testing and organized data systems matter for understanding who is affected and how diagnosis happens in real life.

In Brazil, a genetic analysis of 119 people with MPS I found 47 different IDUA mutations, including 13 that had not been reported before. Even with this variety, two mutations were especially common: p.Trp402Ter (42.4% of alleles) and p.Pro533Arg (16%). This kind of country-specific mutation map helps explain why some genetic tests may find a clear answer quickly in some families, while others may need broader testing because the mutation is less common or newly described.

In India, a government-supported national biobank for lysosomal storage disorders collected samples and linked clinical, enzyme, urine, and genetic data from 530 patients across 27 disorders over 17 years. Within the Hurler group in this resource, one recurrent IDUA variant (c.1469T>C) was reported in 29.4% of cases in their dataset, showing that the most common variants can differ by region. The biobank report also noted that a few people who had a biochemical diagnosis did not have a causative genetic variant found using one of the genetic methods, highlighting that genetic confirmation can sometimes be more complicated than expected.

For patients and caregivers, this month mainly adds understanding of diagnosis rather than changing treatment choices. It becomes clearer that genetic results can vary a lot by family and by country, and that each region may have its own more common IDUA variants, which can affect how straightforward genetic confirmation is. It also becomes clearer that large, organized sample collections can support more consistent diagnosis and future research, while also showing that some people may have clear enzyme-based evidence of disease even when a specific gene change is not found by a given test.

What remains uncertain from these reports is how well any specific variant predicts day-to-day symptoms or long-term outcomes, because those links were not the main focus here. These studies are still useful now because they expand the catalog of known IDUA mutations and show practical steps countries are taking to improve testing and data sharing, which may support earlier recognition and more reliable confirmation in the future.

Limitations

These reports focused on diagnosis and genetic variation, not on testing new treatments.
They did not clarify how specific IDUA variants relate to day-to-day symptoms or long-term outcomes.
Some people had enzyme-based evidence of disease even when one genetic method did not find a causative change.

Important information

This document summarizes recent research from PubMed-indexed publications using automated methods.
It is intended for educational purposes and does not replace medical advice.
Links to the original studies are provided via PubMed, where readers can explore abstracts and, when available, access full-text articles.
Some studies may include additional details that were not accessible for this summary.
Readers seeking more complete detail or context may find it helpful to review the original studies directly.